Eli Lilly expands oncology and neuroscience collaborations with OmniAb and Amplia Therapeutics

Eli Lilly is adding to its external research network, announcing new global collaboration deals aimed at drug discovery in neuroscience and a separate clinical trial partnership in oncology. The moves, described in a report published by Yahoo Finance on Aug. 18, come as large drug developers increasingly rely on outside expertise and platforms to feed early-stage pipelines.

In neuroscience, Lilly said it entered a global collaboration with OmniAb, a deal focused on ion channel drug discovery. Ion channels are proteins embedded in cell membranes that control the flow of ions, and they are a long-running target class in neurological and psychiatric drug research. A collaboration of this type typically involves joint work to identify and optimize molecules that can modulate those channels, with the goal of generating candidates that Lilly can advance.

For oncology, Lilly disclosed a trial partnership with Amplia Therapeutics tied to KRAS G12C-mutant lung cancer. KRAS is a gene frequently altered in cancers, and the G12C mutation is one specific change that has been the target of a growing set of targeted therapies in recent years. A trial collaboration suggests Lilly expects to evaluate a therapeutic approach in patients with that molecular subtype of lung cancer, though the specifics were not detailed in the Yahoo Finance report.

The company’s announcement also frames the partnerships as part of Lilly’s broader effort to build differentiated assets across therapeutic areas. Rather than presenting these deals as late-stage or near-term products, the language in the report emphasizes discovery and trial collaboration structures, which are commonly used to share risk and accelerate early development.

While the announcement identifies the collaborators and broad therapeutic focus areas, key deal terms were not provided in the report. That includes what Lilly and its partners will contribute to costs and resources, whether Lilly will have exclusive rights to any resulting candidates, and any milestone payments or regulatory and commercialization arrangements.

On the clinical side, the report did not specify the trial phase, the study design, the endpoints being targeted, or how patient enrollment would be managed. It also did not state whether Amplia Therapeutics is supplying a particular investigational agent, whether Lilly is contributing a compound or platform, or how the two efforts will be integrated in the protocol.

Sector context matters because partnerships have become a central feature of how pharma expands pipelines, especially in areas that are technically complex. Ion channel drug discovery can require strong capability in biologics or chemistry and careful pharmacology design, while KRAS-driven oncology trials depend heavily on patient selection and biomarker strategy.

Investors and analysts are likely to watch for clearer disclosure in future filings or press releases that specify development timelines, expected data readouts, and whether the programs are positioned as new internal growth areas or extensions of existing strategies. Next, Lilly’s subsequent communications may also clarify the regulatory pathway and how these collaborations fit into the company’s overall oncology and neuroscience priorities.